August 16, 2017

EnteroMedics Announces Presentations Highlighting vBloc and Gastric Vest at IFSO Annual Conference

ST. PAUL, Minn., Aug. 16, 2017 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company and its products will be the subjects of two oral presentations at the 22nd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) taking place in London from August 29, 2017 to September 2, 2017.

EnteroMedics Inc. logo

"I am so pleased to see EnteroMedics' products being highlighted at IFSO, which is one of the largest global stages for bariatric surgeons," commented Scott Shikora, M.D, F.A.C.S., F.A.S.M.B.S., Professor of Surgery at Harvard Medical School; Director of the Center for Metabolic and Bariatric Surgery at Brigham and Women's Hospital in Boston; Consulting Medical Director, EnteroMedics, "I truly believe that vBloc and the Gastric Vest will be game changers in the future of minimally invasive metabolic and bariatric surgery."

There will be two presentations at IFSO dedicated to EnteroMedics' products:

Thursday, August 31, 2017: 2:45PM - 3:00PM


Great Hall



Presentation Title:

C1.4: The Vagus Nerve as a Target for Bariatric and Metabolic Interventions Is There a Future?


Scott Shikora, M.D.

Thursday, August 31, 2017: 5:10 PM-5:30 PM 





Presentation Title:

Gastric Vest


Juan Antonio Lopez Corvala, M.D., Professor of Surgery, Medical Faculty of the Autonomous University of Baja California; Leader in Bariatric Surgery Program, Hospital Ángeles Tijuana.

For more details on IFSO and the 22nd World Congress, please visit

About vBloc® Therapy

vBloc Therapy works to control sensations of hunger using a pacemaker-like device that is implanted under the skin during a safe, minimally invasive procedure that does not alter or remove any patient anatomy. The vBloc System is designed to give the patient a sensation of fullness, empowering them to eat less, control their appetite, and lose weight. Studies have shown that vBloc Therapy produces meaningful weight loss while also reducing comorbidity factors related to obesity.

vBloc Therapy is approved for use in people aged 18 years and older who are obese, with a BMI of 40 to 45 kg/m2, or a BMI of 35 to 39.9 kg/m2 with a related health condition such as Type 2 diabetes, high blood pressure, high cholesterol levels or obstructive sleep apnea who have had a poor response to trying to lose weight under supervision in the last 5 years.

About the Gastric Vest System

The Gastric Vest System (GVS) is an investigational, minimally invasive, laparoscopically implanted medical device being studied for weight loss in obese and morbidly obese patients. The device wraps around the stomach, emulating the effect of conventional weight-loss surgery, and is intended to enable gastric volume reduction without permanently changing patient anatomy.

About EnteroMedics Inc.

EnteroMedics is a medical device company focused on the development and commercialization of technology to treat obesity and metabolic diseases. vBloc® Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like device called the vBloc® System, is designed to help patients feel full and eat less by intermittently blocking hunger signals on the vagus nerve. EnteroMedics recently acquired the Gastric Vest System™ through its acquisition of BarioSurg, Inc.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this release include the belief that vBloc and the Gastric Vest will be game changers in the future of minimally invasive bariatric surgery. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience with our vBloc® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; the competitive industry in which we operate; our ability to maintain compliance with the Nasdaq continued listing requirements; our ability to commercialize our vBloc® System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our vBloc® System; physician adoption of our vBloc® System and vBloc® Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in Exhibit 99.3 of our current report on Form 8-K filed July 26, 2017. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


View original content with multimedia:

SOURCE EnteroMedics Inc.

News Provided by Acquire Media

Close window | Back to top

Copyright 2018 ReShape Lifesciences